Mission Therapeutics raises $13.3 million to progress first-in-class Parkinson’s disease candidate MTX325 through clinical trials
- Financing will support the full execution of Phase Ib proof-of-mechanism study of MTX325 in patients with Parkinson’s disease (PD)
- Comes after successful completion of Phase 1a studies of MTX325, a first-in-class and potentially disease-modifying treatment for PD, in healthy volunteers
- Phase Ib study due to start in H1 2026
Cambridge, UK – October 15, 2025 – Mission Therapeutics (“Mission” or the “Company”), a clinical-stage biotech developing first-in-class therapeutics that promote cell and organ health by enhancing mitophagy, today announces it has raised $13.3 million to progress the clinical development of its lead candidate MTX325 through a Phase Ib proof-of-mechanism study in patients with Parkinson’s disease. The financing was led by current investors.
